TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06432816

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NANO-PSO
Description: NANO-PSO or Oil of pomegranate seed with nanotechnology, they are capsules with a net content of 640 mg with a dosage indicated by sponsor of 2 capsules in fast

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo physically identical to NANO-PSO capsules:~Soft gelatin capsules 640 mg edible oil 35for PLACEBO Oil edible, oval shape, 640 mg.
Study: NCT05209607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Medical and bundle management
Description: Based on the current follow-up management platform of respiratory disease, the WeChat official account will be designed and used to provide health education for patients, such as smoking cessation, reasonable diet, appropriate exercise, etc., and monitor some physiological indicators (such as body temperature, weight, the score of mMRC, etc.) and guide patients to standardize medication and pulmonary rehabilitation.

Intervention type: OTHER
Group type: OTHER
Intervention: Mobile Medical and standard of care
Description: Based on the mobile medical, participants will receive advice on standard medication only.
Study: NCT04877769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: administered twice daily (BID) for 2.5 days (5 doses in total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: administered twice daily (BID) for 2.5 days (5 doses in total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: administered twice daily (BID) for 2.5 days (5 doses in total)
Study: NCT04595162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC019F
Description: GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.
Study: NCT03612050

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Meaning Centered Psychotherapy
Description: Manualized, 3-session existential psychotherapy (30-45 minutes/session) with an optional 4th booster session. Content focuses on enhancing patients sense of meaning and purpose in life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning Centered Psychotherapy
Description: Manualized, 3-session existential psychotherapy (30-45 minutes/session) with an optional 4th booster session. Content focuses on enhancing patients sense of meaning and purpose in life.
Study: NCT05047601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332
Description: PF-07321332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332
Description: PF-07321332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-07321332
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for PF-07321332
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ritonavir
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Ritonavir
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir
Study: NCT05432518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.
Study: NCT05124210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Sotrovimab will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Sotrovimab will be administered.
Study: NCT05173766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ergonomic principls
Description: Ergonomic principles for posture correction in office for computer users.
Study: NCT06412432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training (ET1+ET2)
Description: Exercise training will consist of continuous aerobic training of moderate intensity on cycle ergometer/treadmill, with a frequency of 2-3 weekly sessions lasting 12 weeks, with exercise intensity of VO2 peak of 40% gradually increasing up to 50-60% of VO2 peak based on individual tolerability and improvement; 55-65% of heart rate at peak; 40-59% of heart rate reserve; 4-6 Metabolic equivalents (METS); the duration of the session will gradually increase from 15-30 min to 45-60 min.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy (No-ET)
Description: Patients will be handled according to optimal medical therapy
Study: NCT06299748

Intervention type: BIOLOGICAL
Intervention: Efgartigimod
Description: Efgartigimod IV or SC

Intervention type: BIOLOGICAL
Intervention: Efgartigimod
Description: Efgartigimod IV or SC
Study: NCT06390462

Intervention type: BEHAVIORAL
Intervention: Interpersonal counseling
Description: A structured psychotherapeutic intervention to prevent depression or treat mild to moderate depression. IPC-A is a brief, individual-based intervention (3-8 sessions). The focus is on interpersonal relations as a factor of resilience in depressive symptoms. IPC-A is a shorter form of IPT-A, developed by prof. Myrna Weissman and team.

Intervention type: BEHAVIORAL
Intervention: Treatment as usual
Description: Any other behavioral or medical support or depression indicated by depressive symptoms or depression. This is based on adolescent, caretaker and professional's report.

Intervention type: OTHER
Intervention: No support, intervention or other treatment
Description: The group will comprise those adolescents who report sustained depression but do not seek or receive support over 6 months of follow-up based on adolescent and caretaker's report
Study: NCT04373616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-24
Description: injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injections
Study: NCT05202249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle layer fixation of thoracic drainage tube
Description: The thoracic drainage tube is fixed on the muscle layer of the uniport
Study: NCT06083428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution Erector Spinae Plane Block
Description: ultrasound guided ESPB - L4 level, unilateral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution - PENG block
Description: ultrasound guided PENG block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Test
Description: Only spinal anesthesia
Study: NCT05835674

Intervention type: DIAGNOSTIC_TEST
Intervention: Early intervention program
Description: At enrollment visit: History and examination, MRI, evaluation of comorbidities, medication and genomic testing. HINE, GMA (if below 5 mo), AIMS, SHAI, PSS and DASS-21 questionnaire.~At 6 mo visit: Examination and evaluation of comorbidities, medication and HINE and AIMS~At 12 mo visit: Examination and evaluation of comorbidities, medication and HINE, AIMS, HAI, PSS and DASS-21 questionnaire.~At 18 mo visit: Examination and evaluation of comorbidities, medication and HINE~At 24 mo visit: Examination and evaluation of comorbidities, medication and HINE, PDMS-2, GMFM-66, BSID-IV-cog, MPOC-20 ,PSS, and DASS-21 questionnaire. GMFCS and Mini MACS if CP.
Study: NCT05899348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iTEST
Description: iTEST is a computerized training intervention delivered on a mobile device that is coupled with individual contacts with a therapist/coach. The mobile components train in improving participant's ability to form accurate judgments about their performance and their rate of functional activities. The intervention involves coaching coupled with automated training that is delivered on a mobile device. The automated training involves daily cognitive tests in which the goal for treatment is to improve judgments of accuracy of self-assessment, and coaching is aimed at applying improving metacognitive awareness to every day activities.
Study: NCT04963738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered as a single SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered as a single SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered as a single SC injection.
Study: NCT04680988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 intravenously every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 intravenously every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1020
Description: SHR-1020 Orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice chemotherapy
Description: Investigators will declare one of the following regimens:Albumin-bound paclitaxel injection, Pemetrexed disodium for injection, Gemcitabine for injection
Study: NCT05718960

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reassurance-alone
Description: To be informed of the absence of organic disease and provided a diagnostic explanation of functional dyspepsia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional dietary advice
Description: To receive the same information as reassurance-alone group but also recommended to eat smaller, regular meals and reduce the intake of caffeine/alcohol/fizzy drinks, fatty/processed/spicy foods, and fibre
Study: NCT05749952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symphonie Aqua Digital System
Description: We will digitally capture (via computer) the shape of your limb, which will create a digital file (computer file) of what the internal shape of your socket should be. This file will then be used with a computer software program to optimize the fit of your prosthesis. This image will be used to create a check socket (temporary socket) to confirm a correct anatomical and comfortable socket. Then the check socket (temporary socket) will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symphonie Aqua System (Non-Digital)
Description: A non-digital weight-bearing socket will be used to create the check socket (temporary socket), which will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symphonie Aqua System (Non-Digital)
Description: A non-digital weight-bearing socket will be used to create the check socket (temporary socket), which will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
Study: NCT05200286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olorofim
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorofim
Description: Single oral dose
Study: NCT05932368

Intervention type: OTHER
Intervention: evaluation
Description: examining files and taking records
Study: NCT04226118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vein Illumintion System device
Description: Spotting veins of a patient by use of a Vein Illumintion System device
Study: NCT01477866

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: citogenex
Description: CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: conventional therapy for colon-rectal cancer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy for colon-rectal cancer
Study: NCT05840588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic Treatment
Description: Antibiotic Amoxicillin or Amoxicillin/Clavulanic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic Treatment
Description: Antibiotic Amoxicillin or Amoxicillin/Clavulanic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium breve PRL2020 treatment
Description: Probiotic Bifidobacterium breve PRL2020
Study: NCT05389215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWN12088
Description: DWN12088 Xmg Tablet (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0mg Tablet (BID)
Study: NCT04229355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEB-TACE plus Sorafenib
Description: Drug-eluting bead transarterial chemoembolization plus sorafenib (400 mg/d, po, bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEB-TACE plus Lenvatinib
Description: Drug-eluting bead transarterial chemoembolization plus lenvatinib (8 mg/d, po, qd)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEB-TACE plus PD-1 inhibitor
Description: Drug-eluting bead transarterial chemoembolization plus PD-1 inhibitor
Study: NCT04896372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACT comprehensive of standard care
Description: The proposed intervention was designed by the authors of the study. It was developed following the main ACT-based manuals, with adjustments according to the users and the context of the study implementation.~Specifically, we developed a practical and interactive intervention, which comprises practical activities such as roleplay and writing activities and imaginative activities supported by metaphors. The sessions are based on the use of age-appropriate language to convey the most complex therapeutic processes easily. According to Strosahl and colleagues' model, sessions will respectively target the components of openness, awareness, and engagement.

Intervention type: OTHER
Group type: OTHER
Intervention: TAU only
Description: adolescents will be assessed by a staff dietician and placed on an individualized hy-pocaloric balanced Mediterranean diet. They will also follow a nutritional counselling aimed at promoting the adoption of a healthy lifestyle. Moreover, they will attend a physical activity program consisting of five training sessions per week lasting one hour each with trainers; In addition, they will be involved in psychological counselling pro-vided once a week by a clinical psychologist, aimed to address psychological factors related to dysfunctional lifestyle habits.
Study: NCT05423392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years
Description: Tooth extraction will be following up with the methodological procedures in order to define the effectiveness of anesthetics during indicated dental procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years
Description: Tooth extraction will be following up with the methodological procedures in order to define the effectiveness of anesthetics during indicated dental procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic dental treatment of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years
Description: Endodontic dental treatment will be following up with the methodological procedures in order to define the effectiveness of anesthetics during dental treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic dental treatment of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years
Description: Endodontic dental treatment will be following up with the methodological procedures in order to define the effectiveness of anesthetics during dental treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative tooth restoration of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years
Description: Conservative tooth restoration will be following up with the methodological procedures in order to define the effectiveness of anesthetics during conservative tooth restoration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative tooth restoration of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years
Description: Conservative tooth restoration will be following up with the methodological procedures in order to define the effectiveness of anesthetics during conservative tooth restoration.
Study: NCT06455748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab/daratumumab and hyaluronidase-fihj
Description: Daratumumab/daratumumab and hyaluronidase-fihj: Dara SC 1800mg subcutaneous (IH) or Dara 16mg/kg intravenously (IV) administered weekly (qwk) x 4 every 2 weeks X 3 doses per month starting C7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide: pom 2-4mg PO day (D) 1-21/28 (adjust dose for renal function).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone: dex C1: 20mg IV D1/8, 20mg PO D2/9 and 40mg PO C1D15 weekly up to C6, then 20mg IV monthly starting C7D1 and 20mg PO D8, 15, 22.
Study: NCT05487183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medoc cutaneous probe
Description: A computer-controlled probe delivers temperatures to the skin to measure pain, OA, and OH

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing
Description: Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer tasks
Description: QST and computer tasks are used to measure changes in pain intensity
Study: NCT05860595

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KL003 cell injection Drug Product
Description: Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.
Study: NCT05228236

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant based protein
Description: A single dose of \~30 g of a plant-based protein blend was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: A single dose of \~30 g of whey protein was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
Study: NCT04915937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Infant Formula
Description: RTF milk-based infant formula with oligosaccharides
Study: NCT05389644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Description: iTBS is a form of repetitive TMS. TMS is a form of non-invasive brain stimulation. In this modality, a current is rapidly passed through a TMS coil. This coil is placed on a subject's scalp. The rapidly discharging current creates a magnetic field perpendicular to the plane of the coil. This magnetic field diffuses through the subject's scalp and skull until it reaches the brain parenchyma. There, it causes focal neuronal depolarization.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Description: iTBS is a form of repetitive TMS. TMS is a form of non-invasive brain stimulation. In this modality, a current is rapidly passed through a TMS coil. This coil is placed on a subject's scalp. The rapidly discharging current creates a magnetic field perpendicular to the plane of the coil. This magnetic field diffuses through the subject's scalp and skull until it reaches the brain parenchyma. There, it causes focal neuronal depolarization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Description: iTBS is a form of repetitive TMS. TMS is a form of non-invasive brain stimulation. In this modality, a current is rapidly passed through a TMS coil. This coil is placed on a subject's scalp. The rapidly discharging current creates a magnetic field perpendicular to the plane of the coil. This magnetic field diffuses through the subject's scalp and skull until it reaches the brain parenchyma. There, it causes focal neuronal depolarization.
Study: NCT04435249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPF-001
Description: Expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold